Company
Imaging Biometrics Ltd
LON:IBAI
Since its inception, Imaging Biometrics has continued to translate the best new image analysis technologies into reliable software applications for routine clinical practice. Working in close collaboration with leading hospitals and medical researchers, the company has further improved and solidified IB Neuro as the gold standard in perfusion MR for brain tumors via stereotactic tissue correlations and outcomes measurements.
81 stories · page 4 of 5
IQ-AI subsidiary Imaging Biometrics making progress on all fronts
A letter to investors from chief executive Michael Schmainda revealed that revenue from annual subscription renewals from existing clients "continue to fuel our business"
IQ-AI mulls 'de novo' route for MRI device
The de novo pathway is specifically designed for novel medical devices
IQ-AI signs partnership with Bayer to provide its software
IQ-AI said it is looking to accelerate the adoption of IB Clinic for healthcare providers through global networks
IQ-AI surges after US FDA submission by Imaging Biometrics subsidiary
Imaging Biometrics' patented artificial intelligence technology eliminates the need for gadolinium-based contrast agents in MRI exams
IQ AI notes success in tumour tissue study
"This relevant and powerful study further validates our decision to develop IB Trax,"
IQ-AI doubles revenues as hospitals resume normal business
A switch to fully automated processing enhancements also helped sales
IQ-AI starts enrolment for brain cancer treatment trial
IQ-AI had to reschedule the trial after a change to the trial agent's encapsulation supplier.
IQ-AI shares gain on glowing end-of-year report for Imaging Biometrics subsidiary
Although marking its own homework to some extent, Imaging Biometrics saw a step-change in revenue in 2021, which was almost double the previous year's return at around US$700,000
IQ-AI signs data deal with St Jude Children's Hospital to advance AI brain imaging technology
"This agreement will accelerate the development and commercialization of IB Zero G," said IA-AI chief executive Trevor Brown.
IQ-AI says prestigious US brain centre signs up for IB Clinic software
The MD Anderson Cancer Center in Houston is renowned for excellence in brain cancer care
IQ-AI raises £620,000 for technology development
Trevor Brown, chief executive, subscribed for £150,000 worth of the placing shares
IQ-AI says new publication shows impact of Imaging Biometrics software solutions
Neurosurgery Open published a study that suggested that IB Clinic should be routinely used to optimise surgical guidance and pathologic diagnosis
IQ-AI venture secures European patent for imaging tech
"This EU patent further extends our leading position in the translation and development of novel MR Imaging technologies,” said Michael Schmainda
IQ-AI inks licence deals for Imaging Biometrics software
"While the pandemic negatively impacted sales earlier this year, we are grateful for the rapid return of sales activity as well as trial evaluations of our software," said Michael Schmainda, CEO of IQ-AI subsidiary IB
IQ-AI reschedules Gallium Maltolate phase I clinical trial
The clinical evaluation has been pushed back to the fourth quarter after a change to encapsulation supplier
IQ-AI appoints financial sector veteran to board
Brett Skelly will join as a non-executive director with immediate effect
IQ-AI starts trading on US OTC market
The listing will provide more efficient access to a new and materially larger pool of prospective US investors
IQ-AI expects sales momentum to continue after first-half revenue doubles
The group made strong progress in its major development initiatives
IQ-AI secures patent for Gad-Free medical imaging software
The company said the technology eliminates the need to intravenously inject contrast agent during medical imaging procedures and underscores the potential of AI and its ability to streamline workflows, enhance diagnostic quality, and improv